London, 4 June 2018 - Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody's / BB+ S&P, both stable) announces the appointment of Henriette Nielsen to the newly created role of Chief Transformation Officer. In this role, Henriette will be responsible for leading a number of initiatives across Hikma's global operations to improve operational efficiency and ensure that Hikma achieves its strategic objectives. She will join Hikma's Executive Committee and will report directly to Siggi Olafsson, Hikma's Chief Executive Officer. Her appointment is effective from 4 June 2018.
Siggi Olafsson said, "Henriette brings extensive experience in pharmaceutical operations and transformation projects and has a strong track record of formulating and executing global strategic initiatives and developing multi-functional work plans. She brings an entrepreneurial attitude that I am confident will fit well within the Hikma culture."
Henriette joins Hikma from Teva Pharmaceuticals USA, where she was most recently Senior Vice President, Chief Transformation Officer, Global Marketing & Portfolio. Her previous experience includes founder of System Matters, a healthcare and impact investing consultancy, and General Counsel and EVP at Actavis Group. She also held senior roles at Alpharma, Netdoktor and Kromann Reumert.
-- ENDS --
Enquiries
Hikma Pharmaceuticals PLC
Susan Ringdal
VP Corporate Strategy and Director of Investor Relations |
+44 (0)20 7399 2760/ +44 7776 477050 |
Virginia Spring Investor Relations Manager |
+44 (0)20 3892 4389/ +44 7973 679502 |
FTI Consulting
Ben Atwell/Brett Pollard |
+44 (0)20 3727 1000 |
About Hikma
Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. We're a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,500 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner in the MENA region, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit www.hikma.com.
